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ABSTRACT
Objectives: The overuse of antimalarial drugs is
widespread. Effective methods to improve prescribing
practice remain unclear. We evaluated the impact of 10
interventions that introduced rapid diagnostic tests for
malaria (mRDTs) on the use of tests and adherence to
results in different contexts.
Design: A comparative case study approach, analysing
variation in outcomes across different settings.
Setting: Studies from the ACT Consortium evaluating
mRDTs with a range of supporting interventions in 6
malaria endemic countries. Providers were governmental
or non-governmental healthcare workers, private retail
sector workers or community volunteers. Each study arm
in a distinct setting was considered a case.
Participants: 28 cases from 10 studies were included,
representing 148 461 patients seeking care for suspected
malaria.
Interventions: The interventions included different
mRDT training packages, supervision, supplies and
community sensitisation.
Outcome measures: Analysis explored variation in: (1)
uptake of mRDTs (% febrile patients tested); (2) provider
adherence to positive mRDTs (% Plasmodium falciparum
positive prescribed/given Artemisinin Combination
Treatment); (3) provider adherence to negative mRDTs
(% P. falciparum negative not prescribed/given
antimalarial).
Results: Outcomes varied widely across cases:
12–100% mRDT uptake; 44–98% adherence to positive
mRDTs; 27–100% adherence to negative mRDTs.
Providers appeared more motivated to perform well when
mRDTs and intervention characteristics fitted with their
own priorities. Goodness of fit of mRDTs with existing
consultation and diagnostic practices appeared crucial to
maximising the impact of mRDTs on care, as did prior
familiarity with malaria testing; adequate human
resources and supplies; possible alternative treatments
for mRDT-negative patients; a more directive intervention
approach and local preferences for ACTs.
Conclusions: Basic training and resources are essential
but insufficient to maximise the potential of mRDTs in
many contexts. Programme design should respond to
assessments of provider priorities, expectations and
capacities. As mRDTs become established, the intensity of
supporting interventions required seems likely to reduce.
Strengths and limitations of this study
▪ This analysis addresses the gap in knowledge
around how to change prescribing practices, a
key question in the era of resistance to anti-
microbial medicines.
▪ The analysis exploits indepth data from 10 inter-
vention studies connected through the ACT
Consortium in order to explore the reasons for
variation in trial outcomes.
▪ A comparative case study approach was used,
allowing trends and patterns to be explored
across contexts in a way not possible within
single studies.
▪ By analysing studies conducted within a consor-
tium, access to unpublished documents, raw
data and qualitative insights from the study
teams allowed a deeper understanding of the
studies and their contexts than is often found in
systematic reviews of published reports.
▪ The extent of variation across the study arms in
terms of context, provider type, intervention
content and study design allowed for exploration
of a range of factors affecting outcomes, but
also created challenges for comparability, neces-
sitating a case study approach.
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BACKGROUND
The substantial overdiagnosis of malaria as a cause of
acute febrile illness has been the focus of global atten-
tion in recent years,1–3 given concerns about the clinical
effects of misdiagnoses, the cost of ﬁrst-line artemisinin-
based combination therapies (ACTs) and emerging
malaria drug resistance.4 5 A policy of universal parasito-
logical testing for malaria was introduced by the WHO
in 2010,6 aiming to reduce overprescription of ACTs.2
Malaria rapid diagnostic tests (mRDTs) have been devel-
oped for use in low-resource settings, making parasite-
based testing possible where microscopy may not be
available or feasible.4
RDTs have been introduced with providers in a range
of sectors.7 However, evidence from evaluations of
mRDT introductions show mixed effects; mRDTs do not
lead to improved targeting of ACTs if providers do not
consistently use the tests or if they ignore test results.8–12
To maximise their potential for improving prescribing
practices, evidence is required of the relative success and
challenges of different types of mRDT intervention in
different contexts.
This paper presents an analysis of the ﬁndings from
10 mRDT intervention studies conducted in Africa and
Afghanistan, for which indepth information was avail-
able about interventions, outcomes and contexts. The
studies, all from the ACT Consortium, represent a large
proportion of the intervention studies on mRDTs
recently conducted in areas of ongoing malaria transmis-
sion. This analysis aimed to identify how mRDTs can be
used to improve prescribing in different contexts by
exploring factors inﬂuencing providers’ use of and
adherence to test results and comparing results of inter-
ventions in different settings.
METHODS
The ACT Consortium is an international research collab-
oration involving more than 20 institutions working on a
systematic series of 25 studies in 10 countries in Africa
and Asia, addressing practical questions in the delivery
of malaria treatment.13 Intervention studies involving
mRDTs were conducted in 10 sites in 6 countries. The
analysis in this paper focuses on these studies because of
the ability it gives to use raw outcome data (allowing
comparable outcomes to be calculated), raw data from
linked qualitative research, unpublished documentation
about intervention content, implementation and con-
textual information as well as insights from the study
teams. This allowed a more detailed and comparable
analysis than could be achieved through reliance on
publications or quantitative data alone.
This analysis used a comparative case study approach,
where each study arm conducted in a distinct setting was
considered a case and outcomes were interpreted in
terms of the study design, intervention content, imple-
mentation and contextual factors.14 This approach suits
investigation of ‘how’ and ‘why’ interventions have an
effect and can highlight comparative general trends and
distinct patterns that are not visible in single cases.15 17
The analysis explored three outcomes:
1. Provider uptake of mRDTs.
The proportion of patients presenting with fever, or
history of fever in past 48 hours (unless speciﬁed
otherwise), who were tested for malaria with an
mRDT, as reported by the provider or patient.
2. Provider adherence to positive mRDT results.
The proportion of patients with a positive mRDT
result (for Plasmodium falciparum malaria), who were
prescribed or received an ACT, the ﬁrst-line drug for
non-severe malaria in all cases, as reported by pro-
vider or patient.
3. Provider adherence to negative mRDT results.
The proportion of patients with a negative mRDT
result who were not prescribed, or did not receive, any
antimalarial as reported by provider or patient (the
effect of negative mRDT results on the use of other
treatments, including antibiotics, in ACT Consortium
studies has been presented in a separate paper).16
The analysis evaluated the impact of different inter-
ventions to introduce mRDTs in different contexts.
Twenty-eight cases (ie, distinct settings or intervention
arms) from the 10 studies were included, with a total of
148 461 patients (see table 1). Twenty cases from 7
studies analysed mRDT uptake, 24 cases from 9 studies
evaluated provider adherence to positive mRDT results
and all 28 cases analysed provider adherence to negative
mRDT results.
The studies took place between 2007 and 2012.
Studies were either individual (n=2) or cluster-
randomised controlled trials (n=6); observational (n=2)
or preintervention/postintervention studies (n=1)
(Tanz2 used different designs in their pilot and main
study, so n=11). Providers targeted were governmental
or non-governmental healthcare workers, private retail
sector workers or community health volunteers. Six
studies took place in East Africa, three in West
AfricaCam1,Nig1,Ghan1 and one in south-central AsiaAfgh1.
One focused only on children under 5 yearsUga2; the
rest included children and adults. See online
supplementary ﬁle 1 for more detailed information
about each study.
All the interventions included basic training on
malaria testing with RDTs for healthcare providers,
however the content, duration and approach varied.
Some interventions included additional activities and
materials such as extra training, supervision and feed-
back, patient information leaﬂets or school-based activ-
ities (see table 2 and online supplementary ﬁle 1).
Three studies compared different training
packagesNig1,Cam1,Tanz2. Six studies compared
intervention effects in different epidemiological
contextsUga2,Tanz1,Nig1,Cam1,Afgh1,Ghan1. Seven studies evalu-
ated an intervention against a control arm where mRDTs
were not made availableUga1,Uga2,Uga3,Nig1,Cam1,Afgh1, Ghan1.
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Table 1 Cases included in analysis
Study Study name Country Providers targeted Cases*
Published
results
Afgh1 Strategies for expanding access to quality
malaria diagnosis in south-central Asia where
malaria incidence is low
Afghanistan Government primary care
providers
Afgh1/a: training; patients individually
randomised to receive either mRDT or
established microscopy, Eastern province
18–20
Afgh1/b: training; patients individually
randomised to receive either mRDT or recently
introduced microscopy, Northern province
Afgh1/c: training; patients individually
randomised to receive either mRDT or clinical
diagnosis (no microscopy available), Northern
province
Cam1 Cost-effectiveness of interventions to support
the introduction of malaria rapid diagnostic
tests in Cameroon
Cameroon Government and mission
providers (in hospitals and
primary care)
Cam1/a1: basic training, Bamenda 21–27
Cam1/b1: basic training, Yaoundé
Cam1/a2: enhanced training, Bamenda
Cam1/b2: enhanced training, Yaoundé
Ghan1 How the use of rapid diagnostic tests
influences clinicians’ decision to prescribe
ACTs
Ghana Government primary care
providers
Ghan1/a: training; patients individually
randomised to receive either mRDT or
microscopy
28–30
Government and private primary
care providers
Ghan1/b: training; patients individually
randomised to receive either mRDT or clinical
diagnosis
Nig1 Costs and effects of strategies to improve
malaria diagnosis and treatment in Nigeria
Nigeria Government primary care
providers, private pharmacies
and private medicine dealers
Nig1/a1: basic training, Enugu 27 31–34
Nig1/b1: basic training, Udi
Nig1/a2: enhanced training, Enugu
Nig1/b2: enhanced training, Udi
Nig1/a3: enhanced training + school activities,
Enugu
Nig1/b3: enhanced training + school activities,
Udi
Tanz1 IMPACT 2: Evaluating policies in Tanzania to
improve malaria diagnosis and treatment
Tanzania Government healthcare providers
(in hospitals and primary care)
Tanz1/a: standard MoH† training, Mwanza,
moderate transmission
35
Tanz1/b: standard MoH training, Mbeya, low
transmission
Tanz1/c: standard MoH training, Mtwara,
moderate transmission
Tanz2 Targeting ACT drugs: the TACT trial Tanzania Government primary care
providers
Tanz2/a1: pilot study, low transmission 36–38
Tanz2/b1: pilot study, moderate transmission
Tanz2/2: basic training
Tanz2/3: enhanced training
Tanz2/4: enhanced training + patient
sensitisation
Continued
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Comparability of findings
Although the studies were co-designed and largely
similar, because of differences in primary study questions
and differences in epidemiology, data collection
methods and evaluation timing, mean pooled analyses
would be inappropriate. For example, mRDT uptake was
reported through provider-completed registers in some
projects and patient exit interviews in others. Some
studies reported adherence in terms of the percentage
of patients prescribed ACTs or antimalarials, while others
reported the percentage of patients who received them.
Stockouts may have affected receipt of medication;
whether prescriptions were affected is unknown, as alter-
native medication may or may not have been offered
when there was a known stockout. The analysis pre-
sented therefore focuses on understanding the reasons
for variation in the results, rather than seeking pooled
point estimates.
Quantitative outcome data were extracted from each
study’s raw data set and reanalysed to maximise com-
parability across studies, using the most comparable
denominators and numerators possible. Study, interven-
tion and context characteristics were extracted from
published and unpublished documents. Where
available, thematic content analysis was undertaken
on qualitative data from providers involved in the
studies (ie, focus group discussionsUga2,Uga3 or
interviewsAfgh1,Ghan1,Tanz1/a,Tanz1/b,Tanz2,Uga1 with health
workers, drug shop vendors or volunteers). In Tanz3,
interviews from a later, related study were analysed,
which included six study providers and six similar pro-
viders who had not been involved in the study but had
comparable mRDT experiences.
The analysis drew on the approaches informing inter-
vention component analysis (ICA)52 and qualitative
comparative analysis (QCA),53 which seek to identify
critical features of interventions. As with ICA, we sought
to identify how interventions differed from one another
and then, as with QCA, identify which factors
appeared to be important. Our initial stage involved
gathering as much information about the interventions
as possible, going broader than the ICA approach by
also capturing information about their delivery and
context. However, our analysis differed from ICA and
QCA, which attempt to characterise and apply scores to
interventions and their characteristics and cross-tabulate
these with outcomes. We found our data were not
amenable to scoring in a quantitative sense, due to
wide variation in the extent and types of information
available. Therefore, our analysis was qualitative,
using a meaning-based approach. Tables were created
for each outcome of interest, with explanatory factors
relating to the intervention, context and study design
(see online supplementary ﬁle 2 for an example).
These were shared with study teams and the ACT
Consortium core scientiﬁc team, with ongoing discus-
sions about the ﬁndings and other potential explana-
tory factors.
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Table 2 Intervention content
Scenario mRDT/malaria training Supervision mRDT/ACT supplies Other intervention activities
Afgh1/a One and a half day training, following the national training
package. This covered performing mRDTs (most, but not all,
practiced testing) and prescribing antimalarials
None mRDTs supplied by study None
Afgh1/b
Afgh1/c
Cam1/a1 One day, didactic session covered three modules: malaria
diagnosis, mRDTs, and malaria treatment
Monthly mRDTs and ACTs supplied
by study
None
Cam1/b1
Cam1/a2 Same as Cam1/1, plus:
Interactive two day training on adapting to change (focused
on WHO malaria treatment guidelines), professionalism and
effective communication
Monthly mRDTs and ACTs supplied
by study
None
Cam1/b2
Ghan1/a Two day training about the sensitivity and specificity of
mRDTs, alternative causes of febrile illness and the Ghana
national guidelines (which indicated presumptive treatment for
children who are <5 years old)
None, but study team
were present
mRDTs supplied by study None
Ghan1/b
Nig1/a1 Half day demonstration on how to use mRDTs, which
included practising conducting one test. They also received a
copy of the WHO job aid, which shows the steps in using an
mRDT
None mRDTs supplied by study None
Nig1/b1
Nig1/a2 Same as Nig1/1, plus:
Two day interactive, seminar-style training, covering how to
test, appropriate treatment for positive and negative results
and effective communication. Those attending were given job
aids (eg, treatment algorithm)
Monthly mRDTs supplied by study None
Nig1/b2
Nig1/a3 Same as Nig1/2 Monthly mRDTs supplied by study School-based activities
Nig1/b3
Tanz1/a Two day training (standard MoH), covering performing
mRDTs (including practical) and prescribing antimalarials
Routine MoH
supervision only
mRDTs supplied by MoH None
Tanz1/b
Tanz1/c
Tanz2/a1 One day training on how to use the mRDT and read the
result. Antimalarial drug use guidelines were reviewed and job
aids provided
None mRDTs supplied by study None
Tanz2/b1
Tanz2/2 Two day, didactic, MoH training on how to use mRDTs,
including practical
Six-weekly, focused on
supplies and reporting
mRDTs supplied by study None
Continued
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Table 2 Continued
Scenario mRDT/malaria training Supervision mRDT/ACT supplies Other intervention activities
Tanz2/3 Same as Tanz2/2, plus:
Three additional 90 min interactive training workshops, with
one session repeated 6–7 months later. These covered:
adapting to the change in the diagnosis and management of
malaria; practice with confidence when using mRDTs: tools to
enable change in managing febrile illness; sustaining the
change in practice. Training on communication skills was
included
Six-weekly, focused on
supplies and reporting
mRDTs supplied by study SMS feedback on own mRDT
uptake and adherence at 5 months
Two times per day motivational
SMS for 15 days
Tanz2/4 Same as Tanz2/3 Six-weekly, focused on
supplies and reporting
mRDTs supplied by study SMS feedback on own mRDT
uptake and adherence at 5 months
Two times per day motivational
SMS for 15 days. Patient leaflets
and posters
Tanz3 Six to 11 days IMCI training (depending on whether refresher
training or for new health workers) which included malaria
diagnosis and treatment, plus 1-week study-specific training
(including good clinical practice, provision of informed
consent, performance and interpretation of mRDT according
to the manufacturer’s instructions). One day of the IMCI
training focused specifically on malaria. Training covered
communication skills
None mRDTs and ACTs supplied
by MoH, with study back up
in the case of stockouts
IMCI training, additional study
salary for providers
Uga1 Two day training session followed a week later by on-site
training in facilities. Training was interactive and included
performing and reading an mRDT, management of a patient
with fever and either a positive or negative mRDT as well as
patient communication. All health workers were invited to
attend the training
Supervision at 6 weeks
and 6 months
mRDTs supplied by MoH,
with study back up in the
case of stockouts
Training on patient-centred
services; training in-charges in
health centre management
Uga2/a Four day interactive training, covering performing and reading
an mRDT, how to prescribe antimalarials, how to deal with
negative cases and communication skills. Providers were also
given pictorial job aids
Close supervision for
first 6 months (prior to
evaluation)
mRDTs and ACTs supplied
by study
Community sensitisation
Uga2/b
Uga3 Four day interactive training to all drug shop vendors, which
covered performing and reading mRDTs, prescribing
antimalarials, how to deal with mRDT negatives and
communicating and negotiating with patients
Close supervision for
first 2 months (prior to
evaluation)
mRDTs and ACTs supplied
by study
Community sensitisation
6
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RESULTS
There was wide variation across cases in all three out-
comes: 12–100% mRDT uptake (ﬁgure 1A); 44–98%
adherence to positive mRDTs (ﬁgure 1B); 27–100%
adherence to negative mRDTs (ﬁgure 1C). All outcomes
were universally high in some casesUga1,Uga2/b,Uga3 and
universally low in othersNig1/a1,Nig1/a3, but in many cases,
the three outcomes did not correspond—for example,
testing was infrequent but adherence to results
highTanz1/a,Tanz1/b,Tanz2/3 or adherence to positives high,
but negatives lowGhan1/a,Ghan1/b,Cam1/a1,Cam1/b1, or vice
versaUga2/a,Nig1/b3.
There were no single factors which alone accounted
for any of the outcomes; successful mRDT uptake and
adherence appeared to result from a combination of
context and intervention characteristics. The analysis
identiﬁed several factors which, taken together, may
account for the heterogeneity observed. The appeal of
the intervention to providers was crucial for all three out-
comes, but each was additionally shaped by other factors.
Factors affecting mRDT uptake
There was wide variation between cases in the use
of mRDTs for febrile patients (see ﬁgure 1A). Providers’
motivation to perform well in the intervention was
associated with uptake, as were familiarity with testing,
adequate human resources and supplies, and the cost of
mRDTs.
Motivation to perform well in the intervention
The range of sectors and contexts in which providers
worked meant that their own priorities varied between
cases. For example, government health workers’ prior-
ities may have included some or all of the following:
treating ill patients, managing their workload in the
light of staff shortages, managing (or ‘rationing’) their
medicine supplies in the face of future shortages, main-
taining their position of authority as a clinician. In con-
trast, while private providers may also have prioritised
treating ill patients, some viewed their role as more of a
business than a healthcare service. As such, their prior-
ities may have been more business-oriented, such as
making a proﬁt and ensuring sufﬁcient customers.
Data on provider priorities were not available for all
cases; for some, qualitative data were available but for
others, anecdotal evidence and study team perceptions
were used. Nevertheless, where the intended use of
mRDTs and associated intervention activities aligned
well with providers’ own priorities, they appeared more
motivated to participate and ‘perform’ well in the inter-
vention, and we observed higher uptake and adherence.
There were a number of explanations for, and/or
factors associated with, higher motivation but political
and ﬁnancial support were often critical. For example,
in Tanz2, carefully developed messages addressing exist-
ing provider principles and practices, as well as Ministry
of Health branding of the intervention (an institution
known to inﬂuence the government health workers in
this setting), appeared to motivate providers. In Uga3,
the drug shop vendors were previously not permitted to
offer testing and this new service, along with the asso-
ciated training, supervision and visible involvement of
the Ministry of Health, gave them a legitimacy they had
previously lacked.48 These vendors also reported
increased customer numbers and associated proﬁts,
enhanced by the study’s free provision of mRDTs and
ACTs for them to sell at a subsidised rate. In Tanz3, gov-
ernment providers were paid a supplement to partici-
pate in the study. Additional unintentional aspects of
studies, such as regular visits or perceived support from
evaluators, may have also helped to improve
outcomesUga3,Tanz2.38
Figure 1 (A) Uptake of malaria rapid diagnostic tests (mRDTs) (% patients with fever or history of fever who were tested for
malaria with an mRDT). (B) Adherence to positive mRDT results (% of patients with a positive mRDT who did receive ACTs).
(C) Adherence to negative mRDTs (% of patients with a negative mRDT results who did NOT receive antimalarials).
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In contrast, where mRDT interventions were not
aligned with provider priorities, we saw lower uptake and
adherence. For example, in Nig1 in the private sector,
providers saw themselves more as vendors than health-
care practitioners. Here, there were anecdotal reports
that they were particularly concerned about losing
money from sales if mRDT results were negative and
wondered whether the public would consider them legit-
imate to test. This was the case in spite of the free provi-
sion of mRDTs to providers by the study team. When
providers viewed the intervention as extra unpaid work
(eg, conducting tests or recording test results), this
affected their motivation. In Uga3, some drug shops
declined to participate in the trial for this reason and in
Uga1, some health facilities hesitated to continue partici-
pating when they felt the work was too much without
remuneration. Here, a misalignment between the provi-
ders’ priorities and the intentions of the intervention
led to a lack of motivation for providers to perform in
line with guidelines.
Familiarity with testing
In most cases, there was little prior experience of
malaria testing, either using mRDT or microscopy.
Although patients were generally keen to be tested for
malaria, it was not typically part of providers’ routine
habits to test. In cases where testing had become part of
the established process of care, mRDT uptake tended to
be higher. For example, in Tanz1/c, mRDTs had already
been scaled up in other districts in recent years, and at
baseline there was substantial microscopy testing, unlike
the other two cases in this study where uptake was
lowerTanz1/a,Tanz1/b. Wide-scale public awareness of
testing may have facilitated uptake, for example, in
Cameroon, where mass communication campaigns coin-
cided with the studyCam1, which saw an increase in
malaria testing in all study arms from baseline.23 Some
interventions incorporated local community sensitisation
activities to increase familiarityUga2,Uga3,Tanz2/4,Nig1/3,
although this appeared insufﬁcient on its own to ensure
high uptake.
Adequate human resources and supplies
Where staff workload was high, or patient numbers
exceeded capacity, particularly in small facilities with
only one staff member, mRDTs were not always
usedUga1,Tanz2/1.
There were adequate stocks of mRDTs in facilities in
most studies, in several cases due to study provision of
additional supplies to avert stockouts. However, stockouts
did occur in some studiesCam1,Tanz1,Tanz2, which was asso-
ciated with lower uptake to some extent. Nevertheless,
even when mRDTs were available, they were not always
used, suggesting other factors were also inﬂuential.
Cost of mRDTs to patients
In most studies, mRDTs were provided free to patients.
In those cases where providers were permitted to charge
patients for mRDTs, higher prices may have affected
their uptake. For example in Nig1, where mRDT uptake
was among the lowest observed, patients were charged
more than the recommended price on average, particu-
larly in the private sector.
Factors affecting adherence to positive mRDT results
ACTs were not consistently prescribed to patients with
positive mRDT results (see ﬁgure 1B). Given the expect-
ation for antimalarial overuse based on previous data,
this ﬁnding was not anticipated and reasons for low
adherence to positive results were therefore not expli-
citly explored during the studies. However, some
explanatory factors driving this outcome did emerge, in
addition to the motivation to perform well in the inter-
vention (discussed above). These were the stability of
ACT supplies and local preferences for different types of
antimalarial.
Stability of ACT supplies
Stockouts of ACTs were associated with variation in
adherence to positive mRDT results; however, this could
not explain all the variation. In some cases, ACT use was
relatively low despite no or few stockouts, whereas in
others, use was high despite stockouts occurring. It may
be that provider conﬁdence in the stability of ACT sup-
plies also inﬂuenced the use and rationing of ACTs,
even when ACTs were available. For example, in Tanz2,
lower rates of adherence to positive mRDTs were
observed in the case where stockouts were most
frequentTanz2/4, even after periods of stockouts were
excluded from the analysis.
Pre-existing antimalarial preferences
Information on pre-existing antimalarial preferences was
gathered from baseline and preintervention surveys,32 49
interview transcriptsTanz1 and unpublished reports,54
although no data were available for ﬁve studiesAfgh1,
Ghan1,Tanz3,Uga1,Uga2. The data suggest an association
between the use of ACTs for positive mRDTs and base-
line preferences for, or use of, ACTs rather than other
antimalarials. For example, in Nig1, where ACT use was
generally low, prior to the intervention, other antimalar-
ials were asked for by patients, prescribed and purchased
more commonly than ACTs.34 In contrast, in Tanz1,
where adherence to RDT positive results was higher,
according to stakeholder interviews, ACTs were patients’
preferred antimalarial. This may have been due to
greater exposure to community sensitisation around
ACTs55 or cultural norms around provider authority
such that patients felt more inclined to change their pre-
ferences in the light of providers’ guidance than was the
case in Nigeria. An alternative explanation relates to the
different roles of the public sector in these countries
and therefore, the different inﬂuence that the choice of
ofﬁcial ﬁrst-line medicines has on preferences. For
example, in Tanzania, public facilities are much more
widely used that they are in Nigeria, so people will have
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become used to the idea of ACTs. In Nigeria, the public
sector is a more limited provider, so making a drug ofﬁ-
cially ﬁrst line may have much less effect on preferences.
Factors affecting adherence to negative mRDT results
There was also wide variation in the proportion of
patients prescribed or given antimalarials in spite of
negative mRDT results (see ﬁgure 1C). In addition to
being motivated to perform well in the intervention (dis-
cussed above), the analysis suggests adherence to nega-
tive mRDTs was also driven in part by the extent to
which mRDTs ﬁtted—or were helped by intervention
activities to ﬁt—into the existing landscape of care
(existing diagnostic and consultation practices). This
included providers’ perceptions of the role of mRDTs in
the diagnostic process and possibilities for alternative
diagnoses and treatment. In addition, the analysis sug-
gests that adherence was affected by the extent to which
the interventions attempted to control clinical practice.
Malaria tests were usually the only diagnostics available
in study facilities. In most cases, test-based malaria diag-
nosis required a substantial shift from reliance on clinical
judgement. In a minority of cases, this shift had already
begun before the evaluation started, for example, in
Tanzania and Zanzibar where mRDT introductions had
begun nationallyTanz1,Tanz3, or where malaria testing
using microscopy was establishedAfgh1/a,Afgh1/b,Tanz1/c.
Here, mRDTs appeared to ﬁt into the landscape of care
more easily and adherence to negative mRDT results was
higher. Where testing was new and did not ﬁt into the
landscape of care so well, even if mRDT use was attract-
ive, adhering to negative results appeared more
difﬁcultAfgh1/c,Cam1,Ghan1,Nig1.
Two factors appeared to facilitate integration of mRDTs
into the landscape of care: providers’ perceptions of the
role of mRDTs in the diagnostic process and whether alter-
native management of illnesses, not involving antimalar-
ials, was possible for those with negative mRDT diagnoses.
Perceived role of mRDTs in diagnostic process
Two main factors inﬂuenced providers’ perceptions of
the role of mRDTs within the process of malaria diagno-
sis: how well mRDTs ﬁtted with the dynamic of consulta-
tions and whether the mRDT results matched their
expectations.
In some cases, providers saw mRDTs as central to the
diagnostic process. For example, community health volun-
teers in Uga2, whose adherence was very high, described
the mRDTs as working as ‘a judge’, and drug shop vendors
in Uga3 saw taking blood as crucial to their enhanced
role. Conversely, some providers felt clinical judgement
should play a more important role in making a diagnosis
than mRDTs. Qualitative data suggested that where
mRDTs challenged clinicians’ expertise and disrupted
traditional consultation practices, this led to lower adher-
ence to negative results Afgh1,Ghan1,Tanz2/1. By questioning
the test’s accuracy, providers were able to reassert their
authority and manage the consultation as usual.18 36
Some interventions aimed to help mRDTs ‘ﬁt’ with
the dynamics of consultations. For example, training
included role-play activities or reﬂections about how
mRDTs would work in practiceCam1/2,Uga1,Uga3,
experimentationTanz2/3. Tanz2/4 and reﬂection facilitated
by multiple training and feedback sessions with
peersCam1/2,Tanz2/3,Tanz2/4,Uga1,Uga2,Uga3; and training on
communicating with patientsCam1/2,Nig1/2, Tanz2/3,Tanz2/4,
Uga1,Uga 2,Uga3. Providers reported positive impressions of
the training’s impact on their interactions with patients
including the importance of talking to patients and
explaining the need for mRDTs or the meaning of their
resultsGhan1,Tanz2/1,Tanz2/3,Tanz1/a,Uga2.
In some cases, mRDT results did not match expecta-
tions; typically, fewer mRDTs were positive than had
been expected, particularly when the tests were ﬁrst
introducedUga3,Tanz2/4,Ghan,1/2. When this happened,
providers placed less emphasis on mRDTs in the diag-
nostic process, preferring to rely more heavily on clinical
judgement. For example, in Cam1/a1, mRDT positivity
rates were just 9%, despite the local perception that
malaria prevalence was high in that area. Several inter-
viewees from different cases explained that it was hard
to trust mRDTs when so many results were
negativeGhan1/b,Nig1,Tanz1/b,Tanz2/4,Uga3, or that they only
trusted them once they had seen some positive mRDT
resultsUga2,Tanz2/4. Providers described a fear of missing
malaria diagnoses, particularly when the frequency of
positive results was lower than expected, and this was
associated with lower adherenceGhan1/1,Ghan1/2,Tanz1/b. In
contrast, providers in Tanz3, where adherence to nega-
tive mRDTs was high, appeared less concerned about
malaria, recognising that prevalence had declined.
Some interventions explicitly aimed to raise awareness of
current malaria epidemiology during trainingTanz2/3,
Tanz2/4,Uga1 in order to (re)set expectations of mRDT
positivity rates; this was also associated with higher
adherence to negative results.
In several cases, providers reported that their trust in
mRDTs grew over timeTanz3, Tanz2/2, Tanz2/3, Uga3. Some
described deliberate ‘experimentation’ to build trust in
results, either by testing with microscopy as well as
mRDTsAfgh1 or by seeing whether mRDT-negative patients
recovered without antimalarialsGhan1,Uga2. Indeed in one
study, this was explicitly encouragedTanz2/3, Tanz2/4.
Conversely, some providers’ accounts showed mistrust
of mRDTs was reinforced by experiences of seeing
patients, or indeed themselves, recover when taking anti-
malarials in spite of a negative mRDT resultUga2/b,Ghan1/a.
Patient follow-up was considered another useful means
of building trustUga2, Ghan1/b. Two interventions
aimed to increase the perceived role of mRDTs by
providing information about mRDTs’ sensitivity and
speciﬁcityTanz1,Tanz2/3,Tanz2/4.36
Alternative treatments for non-malarial fever patients
Interventions offered different options for dealing with
mRDT-negative patients (as mentioned above, data on
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the use of alternative treatments are presented in a separ-
ate paper). It appeared that expectations and options for
alternative management of negative cases—in terms of
providers’ role, knowledge of case management and
availability of other medicines—were important in anti-
malarial prescribing to mRDT-negative patients. In the
public facility interventions where detailed guidance was
given to aid alternative diagnosesUga1,Tanz2,Tanz3, adher-
ence was higher than in public facilities where no sub-
stantial guidance was providedGhan1,Afgh1 or where it was
recommended that providers only offer antipyretics to
mRDT-negative patientsNig1/2,Nig1/3. At the community
level, where volunteer providers were not expected
(or permitted) to provide medicines beyond
antimalarialsUga2, adherence to negative results was high.
In private shops in Uganda, where no training on non-
malarial febrile illness management was provided, adher-
ence to mRDT-negative results was still high in terms of
ACT prescription, although here mRDT-negative patients
ended up being sold other medicinesUga3.
Directive intervention approach
Some interventions were more directive about provider
practices, particularly regarding the use of unambiguous
guidance and supervision or surveillance.
Adherence was typically higher if interventions
instructed that no antimalarial should be given to those
with negative mRDT resultsUga1,Uga2,Uga3,Tanz3. In con-
trast, adherence was lower when an intervention allowed
exceptions for when antimalarials could be given in
spite of a negative result, for example, if a febrile patient
was under 5 years and had travelled a long distance to
seek careAfgh1,Tanz2/2,Cam1.
The highest adherence was observed among providers
who had been closely supervised—either for an intense
period after trainingUga2,Uga3 or throughout the evalu-
ation periodTanz3. Providers receiving feedback by text
message experienced these as a form of surveillance,
and reported responding by feeling they should follow
guidelines even if their clinical judgement was at odds
with thisTanz2/3,Tanz2/4.
DISCUSSION
This analysis addresses the persisting gap in knowledge
around how to change prescribing practices. This is a
key question in this time of international concern over
resistance to antimicrobial medicines, with the impera-
tive to optimise medicine use agreed on by United
Nations signatories.56 57 By analysing indepth data from
10 co-designed intervention studies from the ACT
Consortium, we identify factors affecting the uptake of
mRDTs and adherence to test results in different con-
texts. The varied ﬁndings suggest that to improve pre-
scribing through mRDTs, interventions must go beyond
basic training in mRDT use and must be tailored to the
needs of providers in particular contexts. Uptake and
adherence were highest where providers were motivated
by the intervention and the tests ﬁtted with the land-
scape of care. Intervention characteristics that aligned
mRDTs with provider priorities included interactive
training that addressed how to manage test-negative
patients in practice, including clinical and interpersonal
aspects of care. Where malaria endemicity is overesti-
mated locally, experimentation and feedback on fre-
quent test-negative cases was important. A directive
approach supported by feedback or supervisory instruc-
tion can yield high adherence to guidelines but may
affect patient-centred care. The results suggest that as
mRDTs become established, the intensity of supporting
interventions required is likely to reduce.
A strength of this analysis was its use of rich data
sources which enabled a more indepth and comprehen-
sive analysis. Although additional insights may have
emerged from inclusion of a wider set of studies, synthe-
sising ﬁndings from published healthcare interventions
is often challenging, with diverse and poorly described
interventions, contexts and methods.58 59 Nevertheless,
our analysis was limited by the fact that not all included
studies were able to provide information on all
characteristics of interest, while for other characteristics
(eg, year and duration), there was too much variation to
identify any patterns. While study samples were generally
sizeable, in some cases where testing rates and/or
malaria prevalence were low, the denominator for adher-
ence outcomes was small. With one exception, where a
government mRDT policy was evaluatedTanz1, all of the
evaluated interventions in this analysis were instigated by
the study teams. As such, there may be aspects of the
interventions, such as RDT supply sources and costs to
providers, which may not apply at scale.
Previous studies have identiﬁed capacity issues as import-
ant in mRDT implementation, such as stafﬁng levels or
overworked staff,9 12 60–64 mRDTor ACT supplies,9 12 61–65
and providers’ conﬁdence in mRDT results.12 61–66 Our
synthesis shows that beyond these issues, the introduction
of the tests had to make sense in context. Some interven-
tions in our analysis additionally included a more directive
approach. While these interventions did achieve the
highest rates of adherence to negative results, the conse-
quences of restricting the autonomy of clinicians in favour
of standardised guidelines need to be weighed up against
the need for clinicians to consider individual patients on a
case-by-case basis.67 Our ﬁnding, that settings where
testing was more familiar used mRDTs more appropriately,
echoes observations from country-level roll-out of
mRDTs,68 69 and suggests that the interventions required
will change over time. Our ﬁnding, that basic training
alone is insufﬁcient to ensure use of the tests as intended,
aligns with ﬁndings from studies of interventions aiming
to change clinical practice in general.4 70
Prior to introducing mRDTs, initial assessments
should be carried out to understand providers’ priorities
and capacities, as well as how easily tests might integrate
into landscapes of care. Although our analysis suggests
that a process of tailoring is required to formulate the
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intervention to best ﬁt each context, certain broad inter-
vention features are likely to be applicable across settings
(see box 1). As these recommendations arise directly
from the data available in our studies, they are not
exhaustive.
These ﬁndings can inform broader antimicrobial stew-
ardship efforts. Malaria is the ﬁrst disease for which
interventions have been systematically evaluated in order
to understand how to change routine prescribing
through rapid diagnostics. The lessons learnt in attempt-
ing to shift from presumptive to test-directed treatment
are relevant for interventions beyond malaria. The inter-
vention and contextual characteristics identiﬁed here
highlight that apparently simple technological solutions
can require complex supporting apparatus when imple-
mented in real life.71 However, these ﬁndings suggest
that as mRDTs become established, the intensity of sup-
porting interventions required is likely to reduce.
Further research could explore whether an initial invest-
ment in mRDTs could establish patterns of care that
allow for other diagnostic tests to be introduced more
easily in the future.
Conclusion
This analysis shows that uptake and adherence to mRDTs
can be high, but this requires either existing contexts
where integrating the tests into practice already makes
sense, or tailored interventions to encourage this. Basic
training and supplies are essential but insufﬁcient to
maximise the potential of mRDTs in contexts where they
do not ﬁt well with the landscape of care. Apparently
simple technological solutions such as mRDTs can
require complex supporting interventions that take
account of how they will be interpreted and used.
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Box 1 Examples of recommended intervention features
Planning
Recognise and address providers’ priorities
Staffing
Ensure sufficient staff numbers for increased workload
Training
▸ Offer longer, more detailed training, incorporating interactive
activities
▸ Include training on communicating with patients
▸ Address process of change to test-based care:
– plan a series of interactive training and/or supervision
sessions
– incorporate role-play activities which address local
challenges
– use reflective activities
▸ Build trust in mRDTs by including:
– discussion of data on changes in malaria prevalence in the
area
– discussion of sensitivity and specificity of mRDTs
– encouragement to cross-check these data with experience
of tests in practice
Guidance
▸ Provide detailed guidance and resources for acceptable case
management for mRDT-negative patients
▸ Consider how directive mRDT guidance should be, balancing
clarity with the need for clinician judgement to make excep-
tions (eg, if patients have travelled far, with limited means of
transportation to return if their condition worsens)
Medical supplies
▸ Ensure providers can be confident in supplies of mRDTs and
ACTs
▸ Keep costs to patients low
Community/patient sensitisation
▸ Conduct patient-oriented sensitisation activities
– where familiarity with testing is low, where frequent false-
positive microscopy has overestimated prevalence, or if
ACTs are not the most common antimalarial used or
demanded by patients
Burchett HED, et al. BMJ Open 2017;7:e012973. doi:10.1136/bmjopen-2016-012973 11
Open Access
group.bmj.com on June 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
the patients and their guardians, providers, data collectors and other study
team members. LSV is an employee of the WHO and DRA is an employee of
the Centres for Disease Control and Prevention.
Disclaimer The views expressed in this article are the views of the authors
and may not necessarily reflect the views of the WHO or CDC.
Contributors HEDB and CIRC designed the study. HEDB conducted the
analysis and drafted the paper; CIRC contributed to analysis and drafting. BL,
FB, KB, AB, KBr, SC, DDL, KE, CG, HH, SL, PM, AM, WM, AMb, OO, DRA,
DS, SS and LSV contributed to data collection. All authors contributed to
study design, analysis and the final write-up and approved the manuscript.
Funding This analysis, as well as the projects it included, was funded by the
Bill and Melinda Gates Foundation, grant number 39640.
Competing interests None declared.
Patient consent No.
Ethics approval ZAMREC, Zanzibar; Ghana Health Service Ethical Review
Committee; UNCST; MU SOMREC; Ministry of Health and National Institute of
for Medical Research, Tanzania; Ministry of Health Institutional Review Board,
Afghanistan; University Committee on Medical and Scientific Research Ethics,
Nigeria; National Ethics Committee, Cameroon; Makerere University IRB;
Uganda National Council for Science and Technology; LSHTM; University of
California San Francisco Committee on Human Research; CDC; IHI, NIMR.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data from the studies included in this analysis can
be found at the ACTc repository: https://actc.lshtm.ac.uk. This includes
outcome data, description of intervention and data collection tools.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. World Health Organization (WHO). New Perspectives: Malaria
Diagnosis. Report of a joint WHO/USAID Informal consultation, 25–
27 October 1999. Geneva, Switzerland: World Health Organization
(WHO), 2000.
2. World Health Organization (WHO). T3. Test. Treat. Track. Scaling up
diagnostic testing, treatment and surveillance for malaria. Geneva:
Global Malaria Programme, 2012 http://www.who.int/malaria/
publications/atoz/t3_brochure/en/
3. World Health Organization (WHO). The use of malaria rapid
diagnostic tests. 2nd edn. Geneva, Switzerland: WHO, 2006.
4. Bell D, Perkins MD. Making malaria testing relevant: beyond test
purchase. Trans R Soc Trop Med Hyg 2008;102:1064–6.
5. Drakeley C, Reyburn H. Out with the old, in with the new: the utility
of rapid diagnostic tests for malaria diagnosis in Africa. Trans R Soc
Trop Med Hyg 2009;103:333–7.
6. World Health Organization (WHO). Guidelines for the treatment of
malaria. 2nd edn. Geneva: WHO, 2010.
7. Mendelson M, Rottingen JA, Gopinathan U, et al. Maximising access
to achieve appropriate human antimicrobial use in low-income and
middle-income countries. Lancet 2016;387:188–98.
8. Odaga J, Lokong JA, Donegan S, et al. Rapid diagnostic tests versus
clinical diagnosis for managing people with fear in malaria endemic
settings. Cochrane Database Syst Rev 2014;(4):CD008998.
9. Rao VB, Schellenberg D, Ghani AC. Overcoming health systems
barriers to successful malaria treatment. Trends Parasitol
2013;29:164–80.
10. Johansson EW, Gething PW, Hildenwall H, et al. Diagnostic testing of
pediatric fevers: meta-analysis of 13 national surveys assessing
influences of malaria endemicity and source of care on test uptake for
febrile children under five years. PLoS ONE 2014;9:e95483.
11. Johansson EW, Gething PW, Hildenwall H, et al. Effect of diagnostic
testing on medicines used by febrile children less than five years in
12 malaria-endemic African countries: a mixed-methods study.
Malar J 2015;14:194.
12. Ochodo E, Garner P, Sinclair D. Achieving universal testing for
malaria. BMJ 2016;352:i107.
13. http://www.actconsortium.org/
14. Pope C, Mays J, Popay J. Synthesizing qualitative and quantitative
health evidence: a guide to methods. Berkshire, England: McGraw
Hill/Open University Press, 2007.
15. Yin RK. Case study research: design and methods. 4th edn.
London: SAGE Publications, 2009.
16. Hopkins H, Bruxvoort KJ, Cairnes ME, et al. The impact of introducing
malaria rapid diagnostic tests on antibiotic prescribing: a nine-site
analysis in public and private health care settings. BMJ 2017, in press.
17. Crowe S, Cresswell K, Robertson A, et al. The case study approach.
BMC Med Res Methodol 2011;11:100.
18. Reynolds J, Wood M, Mikhail A, et al. Malaria “diagnosis” and
diagnostics in Afghanistan. Qual Health Res 2013;23:579–91.
19. Leslie T, Mikhail A, Mayan I, et al. Overdiagnosis and
mistreatment of malaria among febrile patients at primary
healthcare level in Afghanistan: observational study. BMJ 2012;345:
e4389.
20. Leslie T, Mikhail A, Mayan I, et al. Rapid diagnostic tests to improve
treatment of malaria and other febrile illnesses: patient randomised
effectiveness trial in primary care clinics in Afghanistan. BMJ
2014;348:g3730.
21. Chandler CI, Mangham L, Njei AN, et al. ‘As a clinician, you are not
managing lab results, you are managing the patient’: how the
enactment of malaria at health facilities in Cameroon compares with
new WHO guidelines for the use of malaria tests. Soc Sci Med
2012;74:1528–35.
22. Mangham LJ, Cundill B, Achonduh OA, et al. Malaria prevalence
and treatment of febrile patients at health facilities and medicine
retailers in Cameroon. Trop Med Int Health 2012;17:330–42.
23. Mbacham WF, Mangham-Jefferies L, Cundill B, et al. Basic or
enhanced clinician training to improve adherence to malaria
treatment guidelines: a cluster-randomised trial in two areas of
Cameroon. Lancet Glob Health 2014;2:e346–58.
24. Wiseman V, Mangham LJ, Cundill B, et al. A cost-effectiveness
analysis of provider interventions to improve health worker practice in
providing treatment for uncomplicated malaria in Cameroon: a study
protocol for a randomized controlled trial. Trials 2012;13:4.
25. Achonduh OA, Mbacham WF, Mangham-Jefferies L, et al. Designing
and implementing interventions to change clinicians’ practice in the
management of uncomplicated malaria: lessons from Cameroon.
Malar J 2014;13:204.
26. Mangham-Jefferies L, Wiseman V, Achonduh OA, et al. Economic
evaluation of a cluster randomized trial of interventions to improve
health workers’ practice in diagnosing and treating uncomplicated
malaria in Cameroon. Value Health 2014;17:783–91.
27. Mangham-Jefferies L, Hanson K, Mbacham W, et al. What
determines providers’ stated preference for the treatment of
uncomplicated malaria? Soc Sci Med 2014;104:98–106.
28. Ansah EK, Narh-Bana S, Epokor M, et al. Rapid testing for malaria
in settings where microscopy is available and peripheral clinics
where only presumptive treatment is available: a randomised
controlled trial in Ghana. BMJ 2010;340:c930.
29. Ansah EK, Reynolds J, Akanpigbiam S, et al. ‘Even if the test result
is negative, they should be able to tell us what is wrong with us’: a
qualitative study of patient expectations of rapid diagnostic tests for
malaria. Malar J 2013;12:258.
30. Chandler CI, Whitty CJ, Ansah EK. How can malaria rapid
diagnostic tests achieve their potential? A qualitative study of a trial
at health facilities in Ghana. Malaria J 2010;9:95.
31. Ezeoke OP, Ezumah NN, Chandler CC, et al. Exploring health
providers’ and community perceptions and experiences with malaria
tests in South-East Nigeria: a critical step towards appropriate
treatment. Malar J 2012;11:368.
32. Mangham-Jefferies L, Hanson K, Mbacham W, et al. Mind the
gap: knowledge and practice of providers treating uncomplicated
malaria at public and mission health facilities, pharmacies and drug
stores in Cameroon and Nigeria. Health Policy Plan
2015;30:1129–41.
33. Wiseman V, Ogochukwu E, Emmanuel N, et al. A cost-effectiveness
analysis of provider and community interventions to improve the
treatment of uncomplicated malaria in Nigeria: study protocol for a
randomized controlled trial. Trials 2012;13:81.
34. Mangham LJ, Cundill B, Ezeoke O, et al. Treatment of
uncomplicated malaria at public health facilities and medicine
retailers in south-eastern Nigeria. Malar J 2011;10:155.
35. Bruxvoort K, Kalolella A, Nchimbi H, et al. Getting antimalarials on
target: impact of national roll-out of malaria rapid diagnostic tests on
health facility treatment in three regions of Tanzania. Trop Med Int
Health 2013;18:1269–82.
36. Chandler CI, Meta J, Ponzo C, et al. The development of effective
behaviour change interventions to support the use of malaria rapid
diagnostic tests by Tanzanian clinicians. Implement Sci 2014;9:83.
12 Burchett HED, et al. BMJ Open 2017;7:e012973. doi:10.1136/bmjopen-2016-012973
Open Access
group.bmj.com on June 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
37. Cundill B, Mbakilwa H, Chandler CI, et al. Prescriber and
patient-oriented behavioural interventions to improve use of malaria
rapid diagnostic tests in Tanzania: facility-based cluster randomised
trial. BMC Med 2015;13:118.
38. Leurent B, Reyburn H, Muro F, et al. Monitoring patient care through
health facility exit interviews: an assessment of the Hawthorne effect
in a trial of adherence to malaria treatment guidelines in Tanzania.
BMC Infect Dis 2016;16:59.
39. Baltzell K, Elfving K, Shakely D, et al. Febrile illness management in
children under five years of age: a qualitative pilot study on primary
health care workers’ practices in Zanzibar.Malar J 2013;12:37.
40. Shakely D, Elfving K, Aydin-Schmidt B, et al. The usefulness of
rapid diagnostic tests in the new context of low malaria transmission
in Zanzibar. PLoS ONE 2013;8:e72912.
41. Chandler CI, DiLiberto D, Nayiga S, et al. The PROCESS study: a
protocol to evaluate the implementation, mechanisms of effect and
context of an intervention to enhance public health centres in Tororo,
Uganda. Implement Sci 2013;8:113.
42. Staedke SG. Evaluating the impact of a public health centre intervention
on management of malaria and health outcomes of children in Uganda
—results from the PRIME & PROCESS studies. Policy Brief 2014.
http://www.actconsortium.org/data/files/resources/109/PRIME-and-
PROCESS-policy-brief-English.pdf (accessed 7 Jun 2016)
43. Staedke SG, Chandler CI, DiLiberto D, et al. The PRIME trial
protocol: evaluating the impact of an intervention implemented in
public health centres on management of malaria and health
outcomes of children using a cluster-randomised design in Tororo,
Uganda. Implement Sci 2013;8:114.
44. DiLiberto DD, Staedke SG, Nankya F, et al. Behind the scenes of
the PRIME intervention: designing a complex intervention to improve
malaria care at public health centres in Uganda. Glob Health Action
2015;8:29067.
45. Lal S, Ndyomugyenyi R, Alexander ND, et al. Health facility
utilisation changes during the introduction of community case
management of malaria in South Western Uganda: an interrupted
time series approach. PLoS ONE 2015;10:e0137448.
46. Mbonye AK, Ndyomugyenyi R, Turinde A, et al. The feasibility of
introducing rapid diagnostic tests for malaria in drug shops in
Uganda. Malar J 2010;9:367.
47. Chandler CI, Hall-Clifford R, Asaph T, et al. Introducing malaria rapid
diagnostic tests at registered drug shops in Uganda: limitations of
diagnostic testing in the reality of diagnosis. Soc Sci Med
2011;72:937–44.
48. Hutchinson E, Chandler C, Clarke S, et al. ‘It puts life in us and we
feel big’: shifts in the local health care system during the introduction
of rapid diagnostic tests for malaria into drug shops in Uganda. Crit
Public Health 2015;25:48–62.
49. Mbonye AK, Lal S, Cundill B, et al. Treatment of fevers prior to
introducing rapid diagnostic tests for malaria in registered drug
shops in Uganda. Malar J 2013;12:131.
50. Mbonye AK, Magnussen P, Chandler CI, et al. Introducing rapid
diagnostic tests for malaria into drug shops in Uganda: design and
implementation of a cluster randomized trial. Trials 2014;15:303.
51. Mbonye AK, Magnussen P, Lal S, et al. A cluster randomised trial
introducing rapid diagnostic tests into registered drug shops in
Uganda: impact on appropriate treatment of malaria. PLoS ONE
2015;10:e0129545.
52. Sutcliffe K, Thomas J, Stokes G, et al. Intervention component
analysis (ICA): a pragmatic approach for identifying the critical
features of complex interventions. BMC Syst Rev 2015;4:f3755.
53. Thomas J, O’Mara-Eves A, Brunton G. Using qualitative comparative
analysis (QCA) in systematic reviews of complex interventions:
a worked example. Syst Rev 2014;3:67.
54. Meta J, Nasuwa F, Kessy J, et al. TACT Formative Research
Analysis Report, 2010.
55. Willey BA, Tougher S, Ye Y, et al. Communicating the AMFm
message: exploring the effect of communication and training
interventions on private for-profit provider awareness and knowledge
related to a multi-country anti-malarial subsidy intervention. Malar J
2014;13:46.
56. World Health Organisation. Global Action Plan on Antimicrobial
Resistance. Geneva, 2015, http://www.who.int/drugresistance/
global_action_plan/en/
57. United Nations. Draft political declaration of the high-level meeting of
the General Assembly on antimicrobial resistance. 2016. http://www.
un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_
GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf
58. Michie S, Fixsen D, Grimshaw JM, et al. Specifying and reporting
complex behaviour change interventions: the need for a scientific
method. Implement Sci 2009;4:40.
59. Hoffmann TC, Erueti C, Glasziou PP. Poor description of
non-pharmacological interventions: analysis of consecutive sample
of randomised trials. BMJ 2013;347:f3755.
60. Kyabayinze DJ, Asiimwe C, Nakanjako D, et al. Programme level
implementation of malaria rapid diagnostic tests (RDTs) use:
outcomes and cost of training health workers at lower level health
care facilities in Uganda. BMC Public Health 2012;12:291.
61. Febir LG, Baiden FE, Agula J, et al. Implementation of the integrated
management of childhood illness with parasitological diagnosis of
malaria in rural Ghana: health worker perceptions. Malar J
2015;14:174.
62. Mubi M, Kakoko D, Ngasala B, et al. Malaria diagnosis and treatment
practices following introduction of rapid diagnostic tests in Kibaha
District, Coast Region, Tanzania. Malar J 2013;12:293.
63. Bastiaens GJ, Bousema T, Leslie T. Scale-up of malaria rapid
diagnostic tests and artemisinin-based combination therapy:
challenges and perspectives in sub-Saharan Africa. PLoS Med
2014;11:e1001590.
64. Boadu NY, Amuasi J, Ansong D, et al. Challenges with
implementing malaria rapid diagnostic tests at primary care
facilities in a Ghanaian district: a qualitative study. Malar J
2016;15:126.
65. Diggle E, Asgary R, Gore-Langton G, et al. Perceptions of malaria
and acceptance of rapid diagnostic tests and related treatment
practises among community members and health care providers in
Greater Garissa, North Eastern Province, Kenya. Malar J
2014;13:502.
66. Asiimwe C, Kyabayinze DJ, Kyalisiima Z, et al. Early experiences on
the feasibility, acceptability, and use of malaria rapid diagnostic tests
at peripheral health centres in Uganda-insights into some barriers
and facilitators. Implement Sci 2012;7:5.
67. Armstrong D. Clinical autonomy, individual and collective: the
problem of changing doctors’ behaviour. Soc Sci Med
2002;55:1771–7.
68. Faust C, Zelner J, Brasseur P, et al. Assessing drivers of full
adoption of test and treat policy for malaria in Senegal. Am J Trop
Med Hyg 2015;93:159–67.
69. Zurovac D, Githinji S, Memusi D, et al. Major improvements in the
quality of malaria case-management under the “test and treat” policy
in Kenya. PLoS ONE 2014;9:e92782.
70. Greenhalgh T, Swinglehurst D. Studying technology use as social
practice: the untapped potential of ethnography. BMC Med 2011;9:45.
71. Beisel U, Umlauf R, Hutchinson E, et al. The complexities of simple
technologies: re-imagining the role of rapid diagnostic tests in
malaria control efforts. Malar J 2016;15:64.
72. Chandler CIR, Webb EL, Maiteki-Sebuguzi C, et al. The impact of
an intervention to introduce malaria rapid diagnostic tests on fever
case management in a high transmission setting in Uganda: A
mixed-methods cluster-randomised trial (PRIME). Plos One. In
press.
73. Staedke, SG, Maiteki-Sebuguzi, C, DiLiberto DD. The impact of an
intervention to improve malaria care in public health centers on
health indicators of children in Tororo, Uganda (PRIME): A cluster-
randomised trial. Am J Trop Med Hyg 2016;95:358–67.
74. Ndyomugyenyi R, Magnussen P, Lal S, et al. Appropriate targeting
of artemisini-based combination therapy by community health
workers using malaria rapid diagnostic tests: findings from
randomized trials in two contrasting areas of high and low malaria
transmission in south western Uganda. Tropical Medicine and
International Health 2016;21:1157–70.
Burchett HED, et al. BMJ Open 2017;7:e012973. doi:10.1136/bmjopen-2016-012973 13
Open Access
group.bmj.com on June 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
malaria RDT uptake and adherence
studies to explore reasons for variation in
diagnostic tests (RDTs): synthesis of 10 
Improving prescribing practices with rapid
Wiseman and Clare I R Chandler
Sarah Staedke, Lasse S Vestergaard, Christopher J M Whitty, Virginia 
Anthony Mbonye, Obinna Onwujekwe, Denise Roth Allen, Delér Shakely,
Liverani, Pascal Magnussen, Andreas Mårtensson, Wilfred Mbacham, 
Kristina Elfving, Catherine Goodman, Heidi Hopkins, Sham Lal, Marco
Anders Björkman, Katia Bruxvoort, Siân Clarke, Deborah DiLiberto, 
Helen E D Burchett, Baptiste Leurent, Frank Baiden, Kimberly Baltzell,
doi: 10.1136/bmjopen-2016-012973
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/3/e012973
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/3/e012973
This article cites 60 articles, 10 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1392)Health services research
 (208)Diagnostics
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
